risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Last edited 07/2022 and last reviewed 08/2022

Risankizumab is a humanised IgG1 monoclonal antibody that specifically inhibits interleukin 23 (IL-23) by binding to its p19 subunit.

NICE state (1):

Risankizumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis (PsA) in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:

  • peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
  • moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
  • had 2 conventional DMARDs and at least 1 biological DMARD

Risankizumab is recommended only if the company provides it according to the commercial arrangement.

Results from the 24-week double-blind portion of the KEEPsAKE 1 trial demonstrate that risankizumab is well tolerated and effective for treating diverse clinical manifestations of PsA in patients who have had an inadequate response or intolerance to DMARD therapy (2)

Results from the 24-week, double-blind portion of this phase 3 clinical trial in patients with active PsA reveal that risankizumab was well tolerated and effective in treating patients who have experienced previous intolerance and/or inadequate response to csDMARDs or prior biological therapies (3)

Reference:

Related pages:

psoriatic arthritis